



DIAGNOS
Your Knowledge Partner

PRESS RELEASE

OCTQB : DGNOD
TSXV : ADK
SOURCE : DIAGNOS Inc.

2019.05.30

DIAGNOS Announces the Opening of Two New Screening Clinics in Hafar al-Batin, to Screen 10,000 Patients in the next Six Months With its Partner Kanhoor Medical Co.

Brossard, Quebec, Canada – May 30th, 2019 - Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOD), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the opening of two screening clinics in Hafar al-Batin in Saudi Arabia with its partner Kanhoor Medical Co. (“Kanhoor”) for 10,000 patients in the next 6 months.

Following the conclusion of a successful trial, Kanhoor is pleased to have signed these two agreements with 2 regional hospitals to screen diabetic patients.

“We are excited to continue our collaboration with Kanhoor. These 2 contracts are another successful demonstration of our strategy to work with Kanhoor as our business partner. We continue to work with them to grow our revenue and market share in Saudi Arabia”, said Yves-Stéphane Couture, Vice-president of DIAGNOS.

About DIAGNOS

DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

Additional information is available at www.diagnos.com and www.sedar.com

For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.